Medigene AG
MDGEF · OTC
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 50.7% | -3.1% | -48.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.7% | 75.7% | 69.9% | 80.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -148.3% | -295.5% | -240.6% | -49.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -150.3% | -310% | -227.5% | -373.1% |
| EPS | -0.52 | -0.37 | -0.28 | -0.91 |
| % Growth | -40.5% | -32.1% | 69.2% | – |
| EPS Diluted | -0.52 | -0.37 | -0.28 | -0.91 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -132.6% | -297.8% | -218.7% | 291.5% |